1. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene

   • Maurizio Viale
   • Maria A. Mariggiò
   • Marino Novi

   OriginalPaper Pages: 359 - 367

2. Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma

   • Elisabeth Miot-Noirault
   • Jean Legault
   • Jean Claude Madelmont

   OriginalPaper Pages: 369 - 378

3. Growth inhibition, G₁-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives

   • Juan Antonio Marchal
   • Houria Boulaiz
   • Antonia Aránega

   OriginalPaper Pages: 379 - 389

4. Inhibitory effect of polypeptide from Chlamys farreri on UVA-induced apoptosis in human keratinocytes

   • Mei Dou
   • YanTao Han
   • YingYi Hou

   OriginalPaper Pages: 391 - 398

5. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines

   • Carmen Plasencia
   • Albert Abad
   • Miquel Taron

   OriginalPaper Pages: 399 - 409

6. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

   • Joachim Gullbo
   • Elin Lindhagen
   • Rolf Larsson

   OriginalPaper Pages: 411 - 420

7. Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer

   • Navneet S. Majhail
   • Mohamad Hussein
   • Ronald M. Bukowski

   OriginalPaper Pages: 421 - 426

8. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

   • Susan M. Chang
   • John Kuhn
   • Michael D. Prados

   OriginalPaper Pages: 427 - 435

9. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

   • Garry H. Schwartz
   • Christopher B. Jones
   • Eric K. Rowinsky

   OriginalPaper Pages: 437 - 448

10. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

    • Samir D. Undevia
    • Nicholas J. Vogelzang
    • Mark J. Ratain

    OriginalPaper Pages: 449 - 458

11. A phase I surrogate endpoint study of SU6668 in patients with solid tumors

    • Henry Q. Xiong
    • Roy Herbst
    • James L. Abbruzzese

    OriginalPaper Pages: 459 - 466

12. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study

    • Robert P. Whitehead
    • Jacqueline K. Benedetti
    • John S. Macdonald

    OriginalPaper Pages: 467 - 473

13. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

    • Devansu Tewari
    • Bradley J. Monk
    • Robert A. Burger

    OriginalPaper Pages: 475 - 480

14. Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study

    • José Luis Firvida
    • Margarita Amenedo
    • Gustavo Losada

    OriginalPaper Pages: 481 - 487